Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SER-214 (Serina Therapeutics, Inc.)
- Development stage
- Unknown
- Lead developer
- Serina Therapeutics
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
SER-214 (formerly SRx-501) is a long-acting, injectable polymer-drug conjugate developed by Serina Therapeutics for the treatment of Parkinson's disease. The drug utilizes Serina's proprietary polyoxazoline (POZ) polymer platform to deliver ropinirole, a non-ergoline dopamine agonist, via a once-weekly subcutaneous injection. By providing continuous dopaminergic stimulation (CDS), SER-214 aims to maintain steady-state plasma levels of ropinirole, thereby reducing the "off" time and dyskinesia associated with the pulsatile stimulation of oral dopaminergic therapies. The POZ platform is designed to be biocompatible and allows for high drug loading with precise control over release kinetics. SER-214 has completed initial Phase 1 clinical testing, demonstrating safety and a pharmacokinetic profile supportive of weekly dosing.
- Other names
- POZ-ropinirolepolyoxazoline-ropinirole conjugate
02
Targets
DRD3 (Dopamine receptor D3)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on SER-214 (Serina Therapeutics, Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SER-214 (Serina Therapeutics, Inc.).